Modified oHSV with HRG for Cancer Therapy

Sun, 12 Apr 2026 04:17:48 +0000
Intellectual Property

The USPTO published patent application US20260097088A1 for a modified oncolytic herpes simplex virus (oHSV) engineered with an expression cassette encoding histidine-rich glycoprotein (HRG) for use in cancer therapy. The invention, filed on August 17, 2023 (Application No. 19113359), leverages virotherapy to selectively target and lyse cancer cells while sparing normal cells. The inventors are Chun-Yu Chen, Pin-Yi Wang, and Timothy P. Cripe.